HUE036381T2 - (-)-(2R,3S)-2-amino-3-hidroxi-3-piridin-4-il-1-pirrolidin-1-il-propán-1-on (L)-(+) tartarát só, eljárás annak elõállítására és alkalmazása - Google Patents

(-)-(2R,3S)-2-amino-3-hidroxi-3-piridin-4-il-1-pirrolidin-1-il-propán-1-on (L)-(+) tartarát só, eljárás annak elõállítására és alkalmazása

Info

Publication number
HUE036381T2
HUE036381T2 HUE14755535A HUE14755535A HUE036381T2 HU E036381 T2 HUE036381 T2 HU E036381T2 HU E14755535 A HUE14755535 A HU E14755535A HU E14755535 A HUE14755535 A HU E14755535A HU E036381 T2 HUE036381 T2 HU E036381T2
Authority
HU
Hungary
Prior art keywords
pyrrolidin
propan
pyridin
hydroxy
amino
Prior art date
Application number
HUE14755535A
Other languages
English (en)
Hungarian (hu)
Inventor
Gyorgy F Ambrus
Katherine C Kurjan
Jacopo Zanon
Giovanna Libralon
Faveri Carla De
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HUE036381T2 publication Critical patent/HUE036381T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56Amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255Tartaric acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
HUE14755535A 2013-08-15 2014-08-14 (-)-(2R,3S)-2-amino-3-hidroxi-3-piridin-4-il-1-pirrolidin-1-il-propán-1-on (L)-(+) tartarát só, eljárás annak elõállítására és alkalmazása HUE036381T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361866155P 2013-08-15 2013-08-15

Publications (1)

Publication Number Publication Date
HUE036381T2 true HUE036381T2 (hu) 2018-07-30

Family

ID=51398940

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14755535A HUE036381T2 (hu) 2013-08-15 2014-08-14 (-)-(2R,3S)-2-amino-3-hidroxi-3-piridin-4-il-1-pirrolidin-1-il-propán-1-on (L)-(+) tartarát só, eljárás annak elõállítására és alkalmazása

Country Status (13)

Country Link
US (2) US9242935B2 (enExample)
EP (2) EP3336079A1 (enExample)
JP (1) JP6486358B2 (enExample)
CN (2) CN108794386B (enExample)
CA (1) CA2921385C (enExample)
DK (1) DK3033327T3 (enExample)
ES (1) ES2664749T3 (enExample)
HU (1) HUE036381T2 (enExample)
NO (1) NO2960430T3 (enExample)
PL (1) PL3033327T3 (enExample)
PT (1) PT3033327T (enExample)
SI (1) SI3033327T1 (enExample)
WO (1) WO2015023816A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3033327T3 (en) 2013-08-15 2018-04-16 Allergan Inc (-) - (2R, 3S) -2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (L) - (+) - tartrate salt, PROCEDURE FOR MANUFACTURING AND USING THEREOF
US9992703B2 (en) * 2016-04-04 2018-06-05 Cisco Technology, Inc. Insertion of management packet into a deterministic track
JP2025506178A (ja) * 2022-02-11 2025-03-07 ギルガメッシュ・ファーマシューティカルズ・インコーポレイテッド 精神状態及び障害を処置するための(ampar-pam)-nmda受容体拮抗薬組合せ療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545745A (en) * 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
US6835831B2 (en) * 2001-11-26 2004-12-28 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
US20090088433A1 (en) * 2005-01-26 2009-04-02 Bertrand Leblond Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008011478A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008011483A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
DK2481407T3 (en) * 2007-03-06 2019-01-07 Allergan Inc RELATIONSHIPS TO USE IN TREATMENT OF COGNITIVE DISORDERS
US8173683B2 (en) * 2007-03-06 2012-05-08 Allergan, Inc. Methods for treating cognitive disorders
US20100105687A1 (en) * 2007-03-06 2010-04-29 Allergan, Inc. Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds
DK3033327T3 (en) 2013-08-15 2018-04-16 Allergan Inc (-) - (2R, 3S) -2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (L) - (+) - tartrate salt, PROCEDURE FOR MANUFACTURING AND USING THEREOF

Also Published As

Publication number Publication date
PT3033327T (pt) 2018-04-04
EP3336079A1 (en) 2018-06-20
CN105555765A (zh) 2016-05-04
SI3033327T1 (en) 2018-05-31
US20160347712A1 (en) 2016-12-01
EP3033327B1 (en) 2018-01-03
WO2015023816A1 (en) 2015-02-19
CN108794386A (zh) 2018-11-13
JP6486358B2 (ja) 2019-03-20
PL3033327T3 (pl) 2018-07-31
EP3033327A1 (en) 2016-06-22
NO2960430T3 (enExample) 2018-01-06
DK3033327T3 (en) 2018-04-16
CN108794386B (zh) 2021-06-22
CA2921385A1 (en) 2015-02-19
JP2016528255A (ja) 2016-09-15
CN105555765B (zh) 2018-05-25
US20150051253A1 (en) 2015-02-19
ES2664749T3 (es) 2018-04-23
US9540328B2 (en) 2017-01-10
HK1224292A1 (zh) 2017-08-18
US9242935B2 (en) 2016-01-26
CA2921385C (en) 2021-10-19

Similar Documents

Publication Publication Date Title
IL240475A0 (en) Tubulin compounds, methods for their preparation and use
EP2997837A4 (en) Disintegrable capsule, manufacturing method for same, and smoking equipment containing said disintegrable capsule
PL3044202T3 (pl) Mieszaniny enancjomerów i sposób wytwarzania takich mieszanin
EP3053978A4 (en) Polishing composition and production method therefor
PT3038656T (pt) Composto de glicosaminoglicano, método de preparação e sua utilização
EP3053977A4 (en) Polishing composition and production method therefor
HUE042470T2 (hu) Eljárás széntartalmú anyagok kezelésére gõz termolízissel
PL3055679T3 (pl) Środek do wykrywania pęknięć, sposób jego wytwarzania i zastosowanie środka do wykrywania pęknięć
GB2513065B (en) Desiccant cap and method of production and use
EP3079679A4 (en) Method of treatment of alopecia with monoterpenoids
GB2516425B (en) Encoder and decoder, and method of operation
ZA201503410B (en) Method of making alpha, omega-diiodoperfluoroalkanes
PT3033327T (pt) L)-(+) tartarato de (-)-(2r,3s)-2-amino-3hidroxi-3-piridin-4-il-1-pirrolidin-1-il-propan-1-ona, seus métodos de produção e utilização
IL245018A (en) A synthetic intermediate of maxaccalitol, a method for its preparation and use
IL241096B (en) Treatment methods
EP3023096A4 (en) Soft capsule coating
ZA201603990B (en) Taxane compound, and preparation method and use thereof
ZA201603682B (en) Taxanes compounds, preparation method therefor, and uses thereof
PL3270912T3 (pl) Kompozycje farmaceutyczne zawierające kompleksy taksan-cyklodekstryna, sposób wytwarzania i sposoby zastosowania
EP3041506A4 (en) A method of treatment
AU2013904712A0 (en) Method of Treatment
AU2013904170A0 (en) Method of treatment
AU2013901359A0 (en) Methods of Treatment
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment